Xog Cusub oo Cusub oo Caafimaad oo Wanaagsan ee Bukaannada Qaba Kansarka Caloosha

Written by editor

Mirati Therapeutics, Inc., oo ah shirkad heer-caafimaad ah oo lala beegsaday oncology, ayaa maanta ku dhawaaqday natiijooyin wax ku ool ah oo ka soo baxay kooxda Wajiga 2 ee daraasadda KRYSTAL-1 ee qiimeynta adagrasib ee qiyaasta 600mg BID ee bukaannada qaba adenocarcinoma ductal pancreatic pretreated iyo burooyinka kale ee caloosha (GI). haynta isku-beddelka KRASG12C, oo ay ku jiraan kansarrada mareenka biliary-ga, lifaaqa, mindhicirka yar, isgoysyada caloosha iyo hunguriga, iyo hunguriga. Natiijooyinku waxay muujiyeen in adagrasib ay muujisay firfircooni caafimaad oo muhiim ah iyo xakamaynta cudurrada ballaaran.

Print Friendly, PDF & Email

Natiijooyinka (Abstract # 519) ayaa la soo bandhigi doonaa maanta 10:00 am ET inta lagu guda jiro kalfadhi degdeg ah oo aan la taaban karin oo ka socda 2022 American Society for Clinical Oncology (ASCO) Symposium Gastrointestinal (GI) Kansarka.      

Dr. Tanios S. Bekaii-Saab, oo ah baaraha daraasadda KRYSTAL-1, ayaa faallo ka bixisay, "Kansarada mindhicirku waa qaar ka mid ah kansarrada ugu badan waxayna sii wadaan inay la xiriiraan natiijooyinka badbaadada liidata inkasta oo ay dhowaanahan jireen horumarro, gaar ahaan bukaannada qaba burooyinka GI isbeddelka KRASG12C. Xogta cusub ee kiliinikada ee lagu soo bandhigay ASCO GI waxay muujineysaa in adagrasib, horjoogaha KRASG12C, uu muujiyay waxqabad caafimaad oo rajo leh bukaanada qaba kansarka ganaca iyo burooyinka kale ee GI. Natiijooyinkani waxay dhisayaan xogta caafimaad ee adagrasib ee hore loo soo sheegay ee kansarka mindhicirka iyo ganaca, aadna waa dhiirigelin, oo dammaanad qaadaya baadhitaan dheeraad ah oo ku saabsan adagrasib goobtan.

Soo koobida Natiijooyinka Caafimaad

• Laga bilaabo Sebtembar 10, 2021, qayb ka mid ah bukaannada qaba kansarrada GI ee haysta isbeddelka KRASG12C ee ka diiwaangashan cududda adagrasib monotherapy (n=30) waxay heleen ugu yaraan laba sadar oo hore oo ah daawaynta ka hortagga kansarka, waxayna lahaayeen dabagal dhexdhexaad ah oo ah 6.3 bilood .

• Bukaannada la qiimeyn karo (n=27), heerka jawaabta ujeeddada (ORR) wuxuu ahaa 41% heerka xakameynta cudurka (DCR)na wuxuu ahaa 100%. Bukaannada la qiimeeyo ee qaba kansarka ganaca (n=10), heerka jawaabta (RR) wuxuu ahaa 50%, oo ay ku jiraan 1 jawaab-celin qayb ah oo aan la xaqiijin (PR); Muddada jawaabta dhexdhexaadka ah (mDOR) waxay ahayd 7.0 bilood, iyada oo la socodka dhexdhexaadka ah 8.1 bilood. Bukaannada qaba burooyinka kale ee GI (n=17), RR wuxuu ahaa 35%, oo leh laba PRs oo aan la xaqiijin; mDOR waxa ay ahayd 7.9 bilood bukaanadan, iyada oo lasocod dhexdhexaad ah ay ahayd 6.3 bilood.

Badbaadada xorta ah ee dhexdhexaadka ah (mPFS) ee bukaanka qaba kansarka ganaca waxay ahayd 6.6 bilood (95% Interval Interval, CI: 1.0, 9.7), iyo bukaanada qaba burooyinka kale ee GI, mPFS waxay ahayd 7.9 bilood (95% CI 6.90- 11.30).

• Qaybta guud ee bukaannada qaba kansarrada GI-is-beddelka ee KRASG12C ee lagu qiimeeyay kooxdan, adagrasib si wanaagsan ayaa loogu dulqaaday, oo leh astaanta badbaadada la maareyn karo. Fasalka 3/4 dhacdooyinka xun xun ee la xidhiidha daawaynta (TRAEs) ayaa lagu arkay 27% bukaanada lagu daweeyay adagrasib, iyada oo aanay jirin wax TRAE ah oo u horseedaya joojinta daawaynta, mana jirin Fasalka 5 TRAEs oo la arkay.

"Waxaan aaminsanahay in adagrasib uu leeyahay profile molecular oo kala duwan, iyo xogta lagu soo bandhigay ASCO GI waxay sii taageertaa kartideeda ugu wanaagsan ee fasalka," ayuu yiri Charles M. Baum, MD, Ph.D., aasaasaha, madaxweynaha iyo madaxa cilmi-baarista iyo horumarinta, Mirati Therapeutics, Inc. "Natiijooyinka waxay muujiyeen waxqabad caafimaad oo wanaagsan oo bukaannada qaba KRASG12C-mutated GI cancers oo lagu daweeyey hal wakiil adagrasib, gaar ahaan kuwa qaba kansarka ganaca halkaasoo ikhtiyaarrada xaddidan yihiin. Waxaan sii wadeynaa inaan si adag u qiimeyno adagrasib oo ah hal wakiil iyo isku-darka daawooyinka kale ee kansarka ee qorshe horumarineed oo ballaaran si loo caawiyo dad badan oo qaba kansarka."

Print Friendly, PDF & Email

War ku saabsan qoraaga

editor

Tifaftiraha madaxa eTurboNew waa Linda Hohnholz. Waxay ku salaysan tahay eTN HQ ee Honolulu, Hawaii.

Leave a Comment